INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
National Cancer Institute
Rockville, Estados UnidosPublicaciones en colaboración con investigadores/as de National Cancer Institute (55)
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis
CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
-
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia
Seminars in Hematology
2022
-
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
-
Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study
Blood Cancer Journal
2021
-
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Genome Medicine, Vol. 13, Núm. 1
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
2020
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2018
-
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598
-
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
Leukemia, Vol. 32, Núm. 3, pp. 675-684
2016
-
Assessment of minimal residual disease in myeloma and the need for a consensus approach
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 21-25
-
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30
-
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222